16 results
8-K
EX-10.1
IMNM
Immunome, Inc.
26 Mar 24
Immunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala
8:05am
companies not only with capital, but with executive talent, strategic, operational, and business development resources, enabling them to design and execute
8-K
EX-99.1
IMNM
Immunome, Inc.
13 Feb 24
Results of Operations and Financial Condition
4:10pm
, as applicable, identifying, recruiting, retaining a diverse pool of qualified talent, training, incentivizing, and integrating our existing new employees
424B3
IMNM
Immunome, Inc.
28 Aug 23
Prospectus supplement
9:10am
with Immunome’s ability to attract and retain talent; and
the risks associated with the need to obtain substantial amounts of financing to continue its … protection to officers to the fullest extent permitted by law in order to attract and retain top talent. Taking into account the limitations on the types
S-4/A
IMNM
Immunome, Inc.
25 Aug 23
Registration of securities issued in business combination transactions (amended)
6:38am
on such timelines;
the risks associated with Immunome’s ability to attract and retain talent; and
the risks associated with the need to obtain substantial … that it is necessary to provide protection to officers to the fullest extent permitted by law in order to attract and retain top talent. Taking
S-4
bnk1 a41zgbz10
8 Aug 23
Registration of securities issued in business combination transactions
4:07pm
PRE 14A
baz8v
7 Apr 23
Preliminary proxy
6:29am
DEF 14A
iazbt2ozdirwxcmdtk
16 Apr 21
Definitive proxy
3:35pm
10-K
0go4t
25 Mar 21
Annual report
5:01pm
424B4
mhcv6h danq7
5 Oct 20
Prospectus supplement with pricing info
5:10pm
S-1/A
g6vu25sxaktq orip
24 Sep 20
IPO registration (amended)
7:18am
S-1
3wfwzv
9 Sep 20
IPO registration
4:19pm
DRS
3cqoek8ij1
12 Aug 20
Draft registration statement
12:00am
- Prev
- 1
- Next